Compare IMMR & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMR | SIGA |
|---|---|---|
| Founded | 1993 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.4M | 223.8M |
| IPO Year | 1999 | 2016 |
| Metric | IMMR | SIGA |
|---|---|---|
| Price | $6.55 | $2.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 336.3K | ★ 535.8K |
| Earning Date | 09-14-2026 | 11-09-2026 |
| Dividend Yield | 4.47% | ★ 22.64% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | 0.09 |
| Revenue | ★ $35,013,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $205.62 |
| P/E Ratio | $39.47 | ★ $29.56 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.25 | $2.51 |
| 52 Week High | $8.05 | $7.11 |
| Indicator | IMMR | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 32.06 | 28.24 |
| Support Level | $6.29 | N/A |
| Resistance Level | $6.83 | $3.43 |
| Average True Range (ATR) | 0.20 | 0.24 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 6.58 | 1.21 |
Immersion Corp is a licensing company focused on the acceleration, and scaling, through licensing, of haptic technologies that allow people to use sense of touch to engage with products and experience the digital world around them. Its patents cover a wide range of digital technologies and ways in which touch-related technology can be incorporated into and between hardware products and components, systems software, application software, and digital content. It operates in two operating segments: Immersion and Barnes & Noble Education. The majority of revenue is derived from Barnes & Noble Education segment which is a contract operator of physical and virtual bookstores for college and university campuses and K-12 institutions across the United States.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.